CJC-1295 – W/DAC – 10mg
B's Research Labs | Research Overview
B's Research Labs CJC-1295 with DAC is a synthetic 29-amino-acid analogue of growth hormone–releasing hormone (GHRH). Its molecular structure incorporates a Drug Affinity Complex (DAC), featuring a maleimide-containing modification designed to interact with albumin. This structural modification distinguishes CJC-1295 with DAC from Modified GRF (1–29), commonly marketed as CJC-1295 without DAC. The DAC component influences the peptide's albumin-binding characteristics, molecular stability, and duration of activity in experimental research models.
CJC-1295 with DAC is of interest in peptide chemistry, molecular biology, receptor-binding studies, and biochemical research involving GHRH receptor systems. Supplied in a 10 mg lyophilized powder format, CJC-1295 with DAC is intended exclusively for controlled laboratory research and analytical applications. Laboratory investigations may focus on peptide stability, molecular structure, albumin-binding interactions, receptor-binding characteristics, biochemical behavior, and analytical characterization under controlled experimental conditions. Research involving CJC-1295 with DAC may also examine GHRH receptor interactions and associated molecular signaling pathways. These investigations remain experimental and do not establish clinical safety, efficacy, or suitability for administration. The non-DAC analogue is available as a separate research compound and may be studied independently due to differences in molecular structure and albumin-binding properties.
RUO — RESEARCH USE ONLY
For in vitro laboratory research and analytical applications only.
NOT FOR HUMAN OR VETERINARY USE. NOT FOR CONSUMPTION, INJECTION, INGESTION, OR CLINICAL ADMINISTRATION.
Not intended for diagnostic, therapeutic, pharmaceutical, cosmetic, or personal use. No claims are made regarding safety, efficacy, or suitability for human or animal applications.
Compound Identification
CJC-1295 with DAC is a synthetic GHRH analogue incorporating a Drug Affinity Complex modification associated with albumin-binding properties.
